BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18097665)

  • 1. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
    Larrieu P; Renaud V; Godet Y; Jotereau F; Fonteneau JF
    Cancer Immunol Immunother; 2008 May; 57(5):745-52. PubMed ID: 18097665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
    Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
    Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
    Storkus WJ; Zeh HJ; Maeurer MJ; Salter RD; Lotze MT
    J Immunol; 1993 Oct; 151(7):3719-27. PubMed ID: 7690811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
    Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
    Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
    Romero P; Gervois N; Schneider J; Escobar P; Valmori D; Pannetier C; Steinle A; Wolfel T; Lienard D; Brichard V; van Pel A; Jotereau F; Cerottini JC
    J Immunol; 1997 Sep; 159(5):2366-74. PubMed ID: 9278327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
    Robbins PF; el-Gamil M; Li YF; Topalian SL; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg SA
    J Immunol; 1995 Jun; 154(11):5944-50. PubMed ID: 7751637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
    Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
    Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
    Loftus DJ; Squarcina P; Nielsen MB; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
    Cancer Res; 1998 Jun; 58(11):2433-9. PubMed ID: 9622085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.
    Rivoltini L; Squarcina P; Loftus DJ; Castelli C; Tarsini P; Mazzocchi A; Rini F; Viggiano V; Belli F; Parmiani G
    Cancer Res; 1999 Jan; 59(2):301-6. PubMed ID: 9927036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes.
    Dionne SO; Smith MH; Marincola FM; Lake DF
    Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human melanoma-specific peptide antigens recognized by HLA-A2 restricted tumor-infiltrating lymphocytes].
    Ge H; Bao Z
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):658-61. PubMed ID: 9275546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
    J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.